focus -WSS

focus

author：comprehensive 2025-09-30 08:49:50 - browse：45

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： CDC wastewater surveillance dashboard to track bird flu hotspots

explore

WSS

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Sanofi strikes deal with Novavax, boosting the vaccine maker

Apple Watch's A

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Study: AI not yet building 'n

leisure time

focus

entertainment

Medicare details structure of new drug price negotiation program

Involuntary treatment for addiction doesn't work

Activists slam private health insurers over coverage restrictions

Bird flu outbreak in cows is latest avian flu curveball

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Psychedelics group wrestles with new pharma identity

Mike Pence clashes with Tucker Carlson in Iowa

23andMe had bad news about my health. I wish a person had delivered it

Georgia court denies Trump's request to quash DA's 2020 election probe

entertainment

CDC wastewater surveillance dashboard to track bird flu hotspots

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Researchers on aging grapple with how to calculate biological age

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Readout LOUD podcast: brain research, obesity drug sales, Novartis

entertainment

explore

knowledge

entertainment